Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben Markman

Showing results (11-20 of 43) with videos related to

Pageof 5
Sort By:
Cancer Reports (Hoboken, N.J.)|July 10, 2021
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institutionSiddharth Menon, Amy Davies, Sophia Frentzas, et al.
Investigational New Drugs|December 27, 2017
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancerMuhammad Alamgeer, D Neil Watkins, Ilia Banakh, et al.
Cancer Cell|April 30, 2021
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapyOliver Klein, Damien Kee, Ben Markman, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
New approaches and targets in advanced colorectal cancerTeresa Macarulla, Jaume Capdevila, José Perez-Garcia, et al.
Oncoimmunology|April 23, 2021
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538Oliver Klein, Clare Senko, Matteo S Carlino, et al.
Cancer|January 24, 2023
Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?Oliver Klein, Damien Kee, Adnan Nagrial, et al.
The Lancet. Oncology|August 6, 2019
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trialMichael Friedlander, Tarek Meniawy, Ben Markman, et al.
Investigational New Drugs|February 17, 2021
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignanciesSarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, et al.
JAMA Oncology|July 31, 2020
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical TrialOliver Klein, Damien Kee, Adnan Nagrial, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumorsKyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Pageof 5

Showing results (11-20 of 43) with videos related to

Sort By:
Pageof 5
Cancer Reports (Hoboken, N.J.)|July 10, 2021
Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six-year experience in a large institutionSiddharth Menon, Amy Davies, Sophia Frentzas, et al.
Investigational New Drugs|December 27, 2017
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancerMuhammad Alamgeer, D Neil Watkins, Ilia Banakh, et al.
Cancer Cell|April 30, 2021
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapyOliver Klein, Damien Kee, Ben Markman, et al.
European Journal of Cancer (Oxford, England : 1990)|September 25, 2009
New approaches and targets in advanced colorectal cancerTeresa Macarulla, Jaume Capdevila, José Perez-Garcia, et al.
Oncoimmunology|April 23, 2021
Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538Oliver Klein, Clare Senko, Matteo S Carlino, et al.
Cancer|January 24, 2023
Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?Oliver Klein, Damien Kee, Adnan Nagrial, et al.
The Lancet. Oncology|August 6, 2019
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trialMichael Friedlander, Tarek Meniawy, Ben Markman, et al.
Investigational New Drugs|February 17, 2021
First-in-human, phase I/IIa study of CRLX301, a nanoparticle drug conjugate containing docetaxel, in patients with advanced or metastatic solid malignanciesSarina A Piha-Paul, Kyaw Z Thein, Paul De Souza, et al.
JAMA Oncology|July 31, 2020
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical TrialOliver Klein, Damien Kee, Adnan Nagrial, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 4, 2014
Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumorsKyriakos P Papadopoulos, Josep Tabernero, Ben Markman, et al.
Pageof 5